We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CTI BioPharma been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CTI BioPharma is a member of the Medical sector. This group includes 1181 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CTI BioPharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CTIC's full-year earnings has moved 7.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CTIC has returned 121.4% so far this year. At the same time, Medical stocks have lost an average of 17%. As we can see, CTI BioPharma is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Esperion Therapeutics (ESPR - Free Report) . The stock is up 17.4% year-to-date.
In Esperion Therapeutics' case, the consensus EPS estimate for the current year increased 4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, CTI BioPharma belongs to the Medical - Drugs industry, a group that includes 218 individual companies and currently sits at #85 in the Zacks Industry Rank. This group has lost an average of 30.8% so far this year, so CTIC is performing better in this area. Esperion Therapeutics is also part of the same industry.
CTI BioPharma and Esperion Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has CTI BioPharma been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CTI BioPharma is a member of the Medical sector. This group includes 1181 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CTI BioPharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CTIC's full-year earnings has moved 7.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CTIC has returned 121.4% so far this year. At the same time, Medical stocks have lost an average of 17%. As we can see, CTI BioPharma is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Esperion Therapeutics (ESPR - Free Report) . The stock is up 17.4% year-to-date.
In Esperion Therapeutics' case, the consensus EPS estimate for the current year increased 4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, CTI BioPharma belongs to the Medical - Drugs industry, a group that includes 218 individual companies and currently sits at #85 in the Zacks Industry Rank. This group has lost an average of 30.8% so far this year, so CTIC is performing better in this area. Esperion Therapeutics is also part of the same industry.
CTI BioPharma and Esperion Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.